Clinical trials: Stage III Unresectable Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine…
- Trial name
- SIENNA (NCT06634199)
- Testing
- Durvalumab
- Where
- 22 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación GECP
Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell…
- Conditions
- Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT01282333
- Testing
- gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients
The purpose of this study is to determine whether concurrent chemoradiotherapy combination with Anlotinib is safe, effective in the treatment of unresectable stage III NSCLC patients.
- Trial name
- NCT03672136
- Testing
- Anlotinib, Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shandong Cancer Hospital and Institute
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II
Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC
The purpose of the study is to determine the feasibility of genomically guided radiation therapy (RT) with concurrent chemotherapy in the management of stage II and III non-small cell lung cancer (NSCLC).
- Conditions
- Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- NCT05873439
- Testing
- Genomically Guided Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Lung Cancer
Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00081302
- Testing
- cetuximab, carboplatin, paclitaxel
- Where
- United States
- Sponsor
- Radiation Therapy Oncology Group
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
The primary objectives of this study are to evaluate the safety and tolerability of CS-7017 administered orally twice a day in combination with carboplatin and paclitaxel, and to assess the pharmacokinetics of CS-7017 in…
- Trial name
- NCT01199055
- Testing
- CS-7017, Carboplatin, Paclitaxel
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Lung Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00032032
- Testing
- carboplatin, paclitaxel, radiation therapy
- Where
- 51 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR)…
- Trial name
- RECEL (NCT01714908)
- Testing
- Erlotinib w Concurrent Radiotherapy, etoposide/cis-platin (EP) w Concurrent Radiotherapy
- Where
- 19 sites in China
- Volunteers
- 100 people
- Sponsor
- Jinming Yu
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
Phase I/II trial to study the effectiveness of combining GTI-2040 with docetaxel in treating patients who have recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Recurrent Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT00074022
- Testing
- GTI-2040, docetaxel, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer
Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy
This is a phase I/II study in Japan to evaluate the safety of EMD531444 and its effects on survival time in patients with stage III unresectable non-small cell lung cancer.
- Trial name
- NCT00960115
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Saline
- Where
- Germany
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic NSCLC - Non-Small Cell Lung Cancer
Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)
This study investigates whether adding magnesium to the standard chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC) can improve treatment outcomes.
- Trial name
- NCT07149649
- Testing
- Magnesiocard, Magnesium Diasporal, Microcrystalline cellulose
- Where
- 11 sites in Switzerland
- Volunteers
- 230 people
- Sponsor
- Swiss Cancer Institute
Stage III NSCLC
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
The use of neoadjuvant immuno-chemotherapy could improve survival outcomes of patients eligible for sequential radio-chemotherapy comparing to the benefit already obtained with maintenance immunotherapy.
- Trial name
- SPORADIC (NCT06656598)
- Testing
- Carboplatin, Paclitaxel, Cemiplimab
- Where
- 25 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Solid Tumours
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
The purpose of the study is to determine a subcutaneous (SC: under the skin) durvalumab + recombinant human hyaluronidase (rHu) dose that yields systemic drug exposure similar to intravenous (IV: into the veins) durvalumab…
- Trial name
- IMFINZI-subQ (NCT07391670)
- Testing
- SC durvalumab + rHu, IV durvalumab, Tremelimumab
- Where
- 19 sites in Australia, Georgia and 3 more
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Lung Cancer
NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.
The purpose of this study is to studying neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib to see how well it works in treating patients with unresectable stage III NSCLC harboring EGFR mutations.
- Trial name
- NEGOTIATE (NCT02347839)
- Testing
- Gefitinib-surgery-gefitinib
- Where
- China
- Sponsor
- Sun Yat-sen University
Non-small Cell Lung Cancer
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
The main purpose of this study was to evaluate safety and efficacy in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab.
- Trial name
- NCT03840902
- Testing
- M7824, Durvalumab, Etoposide
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 153 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced…
- Conditions
- Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, Non Small Cell Lung Cancer, Non-small Cell Lung Cancer Metastatic
- Trial name
- NCT07250477
- Testing
- Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment., Standard of Care
- Where
- 4 sites in United States
- Volunteers
- 56 people
- Sponsor
- University of California, Davis